for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Caladrius Biosciences Inc

CLBS.OQ

Latest Trade

2.60USD

Change

0.02(+0.78%)

Volume

2,896

Today's Range

2.52

 - 

2.71

52 Week Range

2.02

 - 

5.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Caladrius Biosciences Reports Positive Results For CLBS16 From Escape-CMD Trial

Nov 16 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS POSITIVE RESULTS FOR CLBS16 FROM ESCAPE-CMD TRIAL AT AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2019.TRIAL INVESTIGATORS OBSERVED PATIENTS HAD HIGH (P=0.0087) INCREASE IN CORONARY FLOW RESERVE AFTER SINGLE INTRACORONARY ADMINISTRATION OF CLBS16.SINGLE ADMINISTRATION OF CLBS16 RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MEASURES OF PATIENT SYMPTOMS AND FUNCTION.TRIAL COMPLETED ENROLLMENT OF TARGETED 20 PATIENTS IN MAY OF 2019.RESULTS FROM SIX-MONTH FOLLOW-UP OF REMAINING TREATED PATIENTS WILL BE AVAILABLE BY YEAR-END 2019..

Caladrius Biosciences Reports Q3 Loss Per Share $0.47

Nov 6 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2019 THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.47.AS OF SEPTEMBER 30, 2019, CALADRIUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $29.2 MILLION.

Caladrius Biosciences Reports Q2 Loss Per Share $0.49

Aug 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2019 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.49.AS OF JUNE 30, 2019, CALADRIUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.7 MILLION.

Caladrius Biosciences Reports Q3 Loss Per Share Of $0.36 From Continuing Operations

Nov 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.36 FROM CONTINUING OPERATIONS.CALADRIUS BIOSCIENCES - AS OF SEPT 30 CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $46.1 MILLION VERSUS $60.1 MILLION AS OF DEC 31, 2017.CALADRIUS BIOSCIENCES - EXPECTS CASH BALANCE WILL ALLOW CO TO FUND CURRENT BUSINESS PLAN BEYOND 2019.

Caladrius Biosciences Q2 Loss Per Share $0.42 From Continuing Operations

Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.42 FROM CONTINUING OPERATIONS.AS OF JUNE 30, 2018, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION.

Caladrius Biosciences Files For Mixed Shelf Of Upto $150 Mln

July 24 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations

May 10 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52 FROM CONTINUING OPERATIONS.

Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

March 22 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.40 FROM CONTINUING OPERATIONS.CALADRIUS - ‍AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $60.1 MILLION VERSUS $7.1 MILLION AS OF DEC 31, 2016​.CALADRIUS BIOSCIENCES - ‍CONFIDENT THAT CASH BALANCES, ADDITIONAL GRANT FUNDING WILL ALLOW IT TO FUND ITS CURRENT BUSINESS PLAN BEYOND 2019​.

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

March 6 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.

Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

Feb 8 (Reuters) - Caladrius Biosciences Inc <CLBS.O>::CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up